Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPW28M)

Drug Name

PD-200390 Drug Info

Synonyms

AC1L4NQF; SCHEMBL9494809; YPPRSIHNTQEZCJ-UHFFFAOYSA-N; 3-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanyl-N-methyl-N-(2-pyridin-2-ylethyl)propanamide; 3-[[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-[2-(2-pyridyl)ethyl]-N-methylpropanamide; 3-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]thio]-N-methyl-N-[2-(2-pyridinyl)ethyl]propanamide

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 188931
TTD Drug ID: DMPW28M

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[3]
Ethosuximide	DMDZ9LT	Epilepsy	8A60-8A68	Approved	[4]
Trimethadione	DM0Q8MZ	Absence epilepsy		Approved	[5]
Paramethadione	DMR5ZUP	Absence epilepsy		Approved	[5]
Methsuximide	DM6L5VO	Absence epilepsy		Approved	[6]
Penfluridol	DMG1DTE	Schizophrenia	6A20	Approved	[7]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[7]
ML218	DM3D21X	Discovery agent	N.A.	Investigative	[8]
KYS-05001	DM3MID9	Discovery agent	N.A.	Investigative	[9]
KYS-05077	DMHW40F	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)	TT729IR	CAC1G_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Synthesis and in vivo evaluation of bicyclic gababutins. Bioorg Med Chem Lett. 2010 Jan 15;20(2):461-4.
2	Pfizer. Product Development Pipeline. March 31 2009.
3	Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
4	Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
5	Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
6	Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
7	Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
8	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
9	Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.
10	Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.